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Background—CPX-351 is a liposome-encapsulated fixed-molar ratio formulation of cytarabine
and daunorubicin that exploits molar ratio-dependent drug-drug synergy to enhance anti-leukemic
efficacy.
Methods—This Phase II study randomized 125 patients 2:1 to CPX-351 or investigator’s choice
of first salvage chemotherapy. Patients with acute myeloid leukemia in first relapse after initial CR
lasting ≥1month were stratified per European Prognostic Index (EPI) into favorable, intermediate,
and poor-risk groups based upon duration of first CR, cytogenetics, age, and transplant history.
Control salvage treatment was usually based on cytarabine and anthracycline, often with one or
more additional agents. Survival at 1-year was the primary efficacy endpoint.
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Results—Patient characteristics were well balanced between the two study arms. Improvements
in efficacy outcomes were observed following CPX-351, but did not meet prospectively defined
statistical criteria for 1-year survival improvement in the overall population. Subset analyses of the
EPI-defined poor-risk strata demonstrated higher response rates (39.3% vs. 27.6%), improvements
in event-free survival (HR=0.63, p=0.08) and overall survival (HR=0.55, p=0.02). Also, 60-day
mortality was lower in the CPX-351 study arm for poor-risk patients (16.1% vs. 24.1%).
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Conclusion—Taken together, the data suggest possible improved outcome in CPX-351-treated
first relapse AML patients with EPI-defined poor-risk disease.

Introduction
Patients with acute myeloid leukemia (AML) who relapse have poor prognosis marked by
reduced response rates, short response duration, and short survival. Absent effective salvage
treatment experimental therapy is considered appropriate.1
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Addition of one or more new agents, e.g. gemtuzumab ozogamicin, fludarabine, or
etoposide, to cytarabine and anthracycline-based treatment regimens, has had limited
success, particularly in patients with poor risk characteristics.2 An alternative approach
would be to optimize the cytarabine and anthracycline treatment backbone itself. In vitro
observations suggest that drug-drug interactions between cytarabine and daunorubicin may
be exploited to improve efficacy for this chemotherapy doublet.3 The ratiometric dosing
hypothesis postulates that efficacy for certain chemotherapy doublets may depend on the
molar ratio of the two drugs and that drug delivery at molar ratios found in vitro to be
consistently synergistic may enhance efficacy.
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CPX-351 is a liposomal formulation of cytarabine and daunorubicin encapsulated at a 5:1
molar ratio, which was found to be maximally synergistic and minimally antagonistic in
vitro3. Liposomal encapsulation markedly increases the plasma half-life of cytarabine and
daunorubicin4, 5 and leads to drug accumulation within the bone marrow6. There is evidence
that drug-containing liposomes may preferentially enter leukemic blasts within the
marrow.6, 7 CPX-351 was markedly active in preclinical leukemia models and in relapsed
leukemia patients. In the phase I study, response was first documented at one-third of the
maximum tolerated dose (MTD) in patients, most of them previously treated with cytarabine
and daunorubicin.4
CPX-351 was compared against investigator’s choice of first salvage treatment in adult
patients with first relapse AML. We hypothesized that CPX-351 would produce better
clinical outcomes than available salvage treatment. No single regimen was acceptable to all
investigators as control, reflecting the absence of effective therapy. Investigators choice of
treatment was expected to include regimens with relatively intensive cytarabine and
anthracycline often with addition of one or more new agents not used in first-line treatment.
Consequently, this study compares liposome encapsulated fixed molar ratio cytarabine and
daunorubicin against salvage regimens administering cytarabine and anthracycline often
with other agents.
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Patients and Methods
Study Design
This is a multi-center, randomized, open-label study conducted in compliance with the
Declaration of Helsinki and the Code of Good Clinical Practices (ClinicalTrials.gov
identifier: NCT00822094). The primary efficacy endpoint was survival at 12-months and
hypothesis generating subset analyses were performed to identify subjects for later study.
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This study was powered to reveal trends (P<0.1) warranting further study in subsequent
clinical trials.
Patients were stratified using the European Prognostic Index (EPI)8, then randomized 2:1 to
receive either CPX-351 or investigator’s choice of salvage therapy. Up to two inductions and
two consolidation courses were to be administered. Allogeneic stem cell transplant (HSCT)
for consolidation was allowed. Monitoring for safety continued until 30 days after treatment
completion and for relapse and survival until 1-year after randomization.
Treatment
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CPX-351 100 units/m2 (1 unit=1.0 mg cytarabine + 0.44 mg daunorubicin) was
administered by 90-minute infusion on days 1, 3, and 5 (first induction) and days 1 and 3
(second induction and consolidation). Control therapy consisted of cytarabine (97.7%) and
anthracycline (77.3%) usually with additional agents (79.4%), such as etoposide (54.5%) or
gemtuzumab ozogamicin (18.2%) (Table 1).
Supportive care included chemotherapy premedication, infection prophylaxis (antibiotic,
antifungal, and antiviral), and hematopoietic growth factors per local practice.
Patient Eligibility
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AML patients with pathologically confirmed previously untreated first relapse, age 18–65,
were eligible. Eligibility required ECOG performance status 0–2, serum creatinine <2.0
mg/dL, total bilirubin <2.0 mg/dL, serum ALT/AST <3 times the upper limit of normal, and
LVEF >50% by echocardiography or MUGA scan. Patients with active second
malignancies, acute promyelocytic leukemia, prior cumulative daunorubicin-equivalent
exposure >368 mg/m2, inability to give full informed consent, active CNS leukemia, New
York Heart Association Class III/IV cardiac impairment, uncontrolled bacterial or invasive
fungal infection, history of copper handling disorder (e.g. Wilson’s disease), and pregnant or
breast feeding women were ineligible.
Assessments
Survival was assessed until 1-year after randomization, event-free survival (EFS) until
documentation of persistent AML, relapse, or death and response was assessed according to
International Working Group criteria.9
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Safety assessments complied with GCP/ICH guidelines, used CTCAE V3.0 criteria, and
included early mortality (at day 30, 60, and 90), serious adverse events, hematological and
non-hematological adverse events, and laboratory assessments.
Statistical Analysis
Chi-square, Fisher’s exact, and Kruskal-Wallis tests were used to assess baseline patient
characteristics. EFS and OS analyses were performed by Cancer Research And Biostatistics,
Seattle, WA using the method of Kaplan and Meier (K-M). Transplanted patients were
censored at the start of conditioning and progression-free patients were censored at last
contact for EFS. Patients alive at last contact were censored for survival. This study had

Cancer. Author manuscript; available in PMC 2017 August 03.

Cortes et al.

Page 4

Author Manuscript

83.6% power (with a one sided alpha=0.1) to detect an absolute increase of 23% (from 27%
to 50%) in survival rate at 1 year.

Results
Patient Characteristics
Eighty-one patients were randomized to CPX-351 and 44 to control over a period of 21
months. The CPX-351 group had younger median age (52 vs. 56 years) and more patients
with secondary AML (12.3% vs. 6.8%). Patient characteristics (Table 2) were well balanced
except for a higher rate of prior transplant in the CPX-351 group (27.2% vs. 15.9%). Most
patients (68%) were in the poor-risk strata.
Treatment Received
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Few patients required two inductions (10/81, 12.3% vs. 3/44, 6.8%). Most CPX-351 patients
achieving CR or CRi had post remission therapy (85%) including 19 (47.5%) with one (15)
or two (4) courses of CPX-351 consolidation, and 15 with allogeneic transplant in place of
CPX-351 consolidation and 13 with transplant following consolidation. All 18 control arm
responders had post-remission therapy: 7 with one (3) or two (4) chemotherapy courses and
11 with HSCT in place of chemotherapy consolidation and 5 with transplant following
consolidation. Similar proportions of patients were transplanted after induction failure
(24.4% vs. 19.2%). Patients transplanted after induction failure had similar outcomes in both
study arms with similar proportions alive >300 days (60% vs. 60%) alive at 201–300 days
(10% vs. 20%), alive 101–200 days (20% vs 20%), and alive <100 days (10% vs. 0%).
Study treatment did not appear to have an effect on the outcomes of patients transplanted
after induction failure.
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Efficacy
Response was more frequent following CPX-351 (30CR (37%) + 10CRi (12.3%) than
control (14CR (31.8%) + 4CRi (9.1%). Factors including duration of first CR, age and
adverse cytogenetics that might have affected the CR rate were examined by multivariate
logistic regression. Duration of first CR of 7+ months (p=0.0001) and adverse cytogenetic
risk (p=0.0022) had a significant correlation with induction response. Age was not a
significant factor.
Kaplan Meier analysis of overall survival (HR=0.75, p=0.33), and EFS (HR=0.66, p=0.08)
did not demonstrate significant differences. (Figures 1A and 1B). Survival at 1-year was
36% vs. 27% (p=0.33).

Author Manuscript

Although outcomes of favorable vs. intermediate vs. poor-risk groups by EPI scoring were
not compared formally due to small numbers in the favorable (n=15, 12%) and intermediate
(n=25, 20%) risk groups, poor-risk patients tended to have lower rates of CR (all patients:
37.0% vs. 31.8%; poor-risk 28.6% vs. 20.7%) and CRi (all patients: 12.3% vs. 9.1%; poorrisk 10.7% vs. 6.9%), higher rates of 60-day mortality (all patients: 14.8% vs. 15.9%; poorrisk 16.1% vs. 24.1%), and median survival was slightly shorter as well (all patients: 8.5

Cancer. Author manuscript; available in PMC 2017 August 03.

Cortes et al.

Page 5

Author Manuscript

mos. vs. 6.3 mos.; poor-risk 6.6 mos. vs. 4.2 mos.). Outcomes assessed by a number of
measures tended to be slightly but consistently worse for the EPI poor risk group.
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The EPI-defined poor-risk strata accounted for 68% (85/125) of all patients and efficacy
differences favoring CPX-351 were observed for this group (Table 2). This CPX-351
subgroup had higher rates of Day 14 morphologic leukemia free bone marrow (66.1% vs.
44.8%, P = 0.07), with higher CR (28.6% vs. 20.7%) and CRi (10.7% vs. 2.9%) rates, a
favorable trend for EFS (HR=0.63, p=0.08), and a statistically significant improvement in
OS (HR=0.55, p=0.02). (Figures 1C and 1D). Survival at 12 months was 28% (19–46%) for
the CPX-351 group and 9% (0–20%) for the control group. A test for the level of
heterogeneity between different strata treated on this study was performed comparing the
CPX-351 poor-risk, CPX-351 non-poor risk, Control poor risk, and Control non-poor risk
strata. Log-rank testing of differences among strata for OS was highly significant
(P=0.0003) and for EFS was significant (p=0.009).
Safety
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Early mortality was similar at 30-days (7.4% vs. 4.5%) and at 60-days (14.8% vs. 15.9%).
By 90-days deaths were more frequent in the control arm (21.4% vs. 37.9%). Sixty day
deaths on the CPX-351 arm were due to infections (8), progressive AML (1), acute
respiratory failure (1), CNS hemorrhage after a fall with head trauma (1), and sudden cardiac
death (1). Sixty day deaths among control arm patients were due to infections (4),
progressive AML (2), and unknown causes (1). CPX-351-treated patients had slower
neutrophil recovery (time to ANC >1000/μL, 42d vs. 34d) and platelet recovery (time to
platelets >100,000/μL, 45d vs. 35d) compared to control. Delayed hematologic recovery was
associated with more infection-related events including: febrile neutropenia, bacteremia,
pneumonia, sepsis, urinary tract infection, pyrexia, and cellulitis but did not increase the rate
of infection-related deaths by day 60 (9.9% vs. 9.1%). The rate of grade 5 adverse events,
regardless of causality, was similar between the two arms (23.5% vs. 20.5%).
Impact of Prior HSCT on Outcomes
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Ninety-six patients (77%) had no history of transplant at study entry with CPX-351 treated
patients having higher CR+CRi rates (54.2% vs. 37.8%) and similar 30-day (3.4% vs.
5.4%), and 60-day mortality (10.2 vs. 16.2%). In contrast, 22 of 29 patients (75.9%) with
prior HSCT were randomized to CPX-351 and had lower response rates (36.4% vs. 57.1%)
and higher 30-day (18.2% vs. 0) and 60-day mortality (27.3% vs. 14.3%) compared with
control (Table 4). Notably, 6 of the 12 CPX-351 patients dying by day 60 had prior HSCT
and the causes included infection (5) and progressive AML (1). One of 7 patients with prior
HSCT randomized to control arm therapy died within 60 days of infection.
Factors Potentially Influencing Outcomes
Post induction transplants were common and equally frequent in the two study arms (46.9%
vs. 47.7%) but were somewhat more frequent in the control arm after CR (73% vs. 86%) and
CRi (60% vs. 100%) (Table 2). Non-responding patients were also transplanted (24.4% vs.
19.2%). Survival after response and transplant was similar in both study arms. CR patients
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and CRi patients across both study arms also had similar survival after transplant.
Transplants had similar impact on both study arms.
The duration of first CR was well balanced between the two study arms with similar
proportions of patients with CR1 duration lasting <6 months (33.3% vs. 36.4%), 7–18
months (53.1% vs. 45.5%), and >18 months (13.6% vs. 18.2%). This result suggests that
differences in study outcomes were not likely due to differences in first CR duration.
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Treatments administered to induce and consolidate first CR were similar between CPX-351
and control groups. Only one patient in each arm received induction treatment with less than
the intensity of conventional 7+3 (1.2% vs. 2.3%) and most patients received 7+3 induction
(55.6% vs. 63.6%) with a substantial minority treated with greater intensity (43.2% vs.
34.1%), usually in the form of another drug added to 7+3. A small minority of patients
received post remission therapy with lower intensity regimens (17.3% vs. 13.6%), while
most patients received HiDAC (66.7% vs. 70.5%) or HiDAC regimens with another drug
added (13.6% vs. 13.6%). Only 2 (2.5%) of CPX-351 patients and 1 (2.3%) control arm
patient received no post remission therapy whatsoever. Somewhat more patients on the
CPX-351 arm had prior HSCT (27.2% vs. 15.9%). Although the numbers are small, there
does not appear to be a marked difference in the amount of chemotherapy administered to
patients in either arm to induce or consolidate their initial response.
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The profile of cytarabine dosing in the control arm was examined. One of 44 patients
received no cytarabine, 4 received 100 mg/m2 (3 patients) or 200 mg/m2 (1 patient) 7 day
infusions of cytarabine, 30 received 1gm/m2/day x5-6 days usually with mitoxantrone
etoposide or fludarabine + gemtuzumab ozogamicin, and the remaining 9 patients received
more intensive cytarabine regimens (>1gm/m2/day x6 days up to 12gm/m2/day×3 days).
Control arm response rates were similar between those receiving the highest dose cytarabine
regimens (9 patients, 33% CR) and those receiving lower doses of cytarabine (30 patients
40% CR). Investigator’s choice of salvage therapy relied mostly on intermediate and higher
doses of cytarabine.

Discussion

Author Manuscript

Patients with first relapse AML have limited likelihood of response and short expected
survival following salvage treatment. For example, mitoxantrone, etoposide, and cytarabine
(MEC) induces response in 23% of patients with median overall survival of only 2 months.10
Modulation of deoxycitidine kinase by fludarabine, led to the combination of fludarabine
and cytarabine, resulting in a 36% CR rate with median remission duration of 39 weeks.11
First salvage gemtuzumab ozogamicin induces CR+CRp response in 30% of patients with
CD33+ AML12 and, for patients with short 1st CR durations, appeared to be superior to
cytarabine-based therapy.13 The need for improved salvage therapy remains evident.
CPX-351 delivers the two most active single agents at a fixed 5:1 molar ratio, shown to be
consistently synergistic in vitro and in preclinical leukemia models3,14 In the current study
patients were prospectively selected, stratified, randomized and treated. Breems, et al8
created a scoring system (EPI) based on duration of first remission, cytogenetics at
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diagnosis, age at relapse and history of transplant, which was used to stratify patients on this
study. The rate of morphologic leukemia free-state assessed at the time of early (Day 14)
response assessment was clearly higher following CPX-351 (76.0% vs. 51.2%) and the rate
of subsequent CR+CRi response assessed at time of hematologic recovery was modestly
improved among all patients (49.4% vs. 40.9%) compared to control. In spite of these
observations, significant improvements in 1-year survival, OS, and EFS were not achieved.
Subset analyses however, indicated that patients in the poor risk strata as defined by the
European Prognostic Index might benefit. Patients with poor-risk EPI scores constituted
66.7% of the patients in the Breems8 series and had an expected 1-year probability of
survival of 16%, very similar to the poor risk strata in our study with 68% of the patients and
9% 1-year survival after control arm treatment. In contrast, the 1-year survival was 29% in
the CPX-351 poor-risk group and the observed response rate was higher as well.
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Improved 1-year survival following CPX-351 in the poor-risk strata is attributed to the
higher rate of response and was associated with a lower rate of 90-day (21.4% vs. 37.9%)
mortality. We speculate that the increased rate of leukemia clearance reflected in the day 14
bone marrow examination (77.3% vs. 59.5%) may reduce the impact of active leukemia on
early mortality, which begins to be seen by day 60 and becomes fully evident by day 90.
Early reduction of tumor burden may delay progression to death, even in patients who do not
ultimately achieve a full CR.
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The longer duration of bone marrow suppression in the CPX-351 arm can be interpreted as
reflecting a more intensive treatment and this view is supported by preclinical evidence of
cytarabine and daunorubicin accumulation within the marrow following CPX-351
treatment.6 Still, the 30 and 60-day induction mortality rates and the rates of nonhematologic adverse events were similar in both study arms, suggesting comparable overall
treatment intensity.
Survival analyses were unlikely to have been affected by post-induction transplants because
the overall rates of transplantation were similar in both arms and because there was no
difference in survival after transplant.

Author Manuscript

An unexpected finding was that patients with stem cell transplants prior to CPX-351
treatment appeared to have poorer outcomes. A disproportionate number of patients with
prior transplant were allocated to the study arm with 6 of 22 patients (27.3%) dying within
60-days after CPX-351 treatment. These six patients were half of all the 60-day deaths on
the CPX-351 arm. While not definitive, these results suggest caution in future studies of
CPX-351 if patients with prior transplant are considered for treatment. The poor outcomes
could be due to leukemia persistence, increased treatment morbidity, or insufficient bone
marrow reserve for timely recovery following CPX-351 therapy. It is premature to conclude
that there is no role for CPX-351 in this population but additional study will be needed to
confirm the safety of treatment for this group. The 96 patients without prior transplant
performed considerably better following CPX-351 treatment with higher rates of response,
similar rates of 60-day mortality and lower rates of mortality by 90 days.

Cancer. Author manuscript; available in PMC 2017 August 03.

Cortes et al.

Page 8

Author Manuscript
Author Manuscript

Although both study arms produced similar outcomes in patients with lower risk disease, the
poor-risk strata tended to respond more often and have better outcomes when treated with
CPX-351 compared to control. This differential response to CPX-351 is consistent with
what is known about the pharmacological and pharmacodynamic actions of CPX-351.
Patients with poor-risk first relapse AML often have adverse cytogenetics and early relapse
(<6 months) following initial treatment with cytarabine and anthracycline and poor outcome
is often associated with altered cellular drug transport, increased drug inactivation, and
altered signaling pathways that inhibit cell cycle-dependent drug action. Poor-risk biology
blunts the effect of treatment by reducing drug levels at sites of pharmacologic action and/or
reducing susceptibility to killing after exposure of drugs to the leukemia cell. For example,
leukemic cells from high-risk patients are more likely to over-express several membraneassociated drug transport proteins, such as MDR1 and MRP, resulting in reduced uptake and
retention of anthracyclines such as daunorubicin and mitoxantrone.16 Evidence from
leukemia cell lines and AML patient blasts obtained from marrow and peripheral blood
indicate that intact CPX-351 liposomes are likely to be internalized by leukemia cells in an
energy-dependent fashion followed by intracellular release of drug.6 These observations help
explain the increased and prolonged cytarabine and daunorubicin drug concentrations within
bone marrow following CPX-351 dosing and suggest that this approach may bypass
membrane transporter-based resistance mechanisms which limit exposure of leukemic cells
to drug. In addition, delivery of excess cytarabine relative to daunorubicin (the 5:1 molar
ratio) may help to reduce the potential for daunorubicin-induced G2/M phase arrest, which
could block leukemic cells from entering S-phase, potentially inhibiting cytarabine action
due to its S-phase specificity. These mechanistic hypotheses need to be confirmed in
subsequent trials.
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Another consideration is that liposomal encapsulation of cytarabine and daunorubicin results
in marked increases in plasma half-life (>24 hours) for both drugs, with a negligible
distribution phase, where detectable plasma drug levels are extended deep into the second
week after the start of induction treatment.4 It is possible that marked prolongation of
exposure to cytarabine and daunorubicin could extend the duration of drug action and
increase treatment-induced cytotoxicity to very slowly replicating leukemic cells. In
addition, leukemic cells from high risk and secondary AML patients with mixed lineage
leukemia (MLL) gene translocations block the functional response of P53 to chemotherapy
in preclinical models, limiting induction of apoptosis to much slower P53-independent
processes.17, 18 The marked increase in plasma half-life of cytarabine and daunorubicin
following CPX-351 administration may extend the period of cytotoxic drug concentrations
enabling effective treatment. In contrast, drug levels rapidly diminish after completing
infusions of unencapsulated cytarabine and anthracycline, with rapid loss of cytotoxicity
against leukemia cells with such phenotypes. These considerations may help to explain why
the impact of CPX-351 treatment is greater on patient populations with more difficult to
treat disease.
In summary, although this randomized study did not meet pre-specified goals for survival at
1-year in the overall patient population, it was able to generate a number of hypotheses
based upon subgroup analyses. Possible clinical benefit after CPX-351 treatment was
observed for patients stratified to the poor-risk subgroup defined by European Prognostic
Cancer. Author manuscript; available in PMC 2017 August 03.
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Index scoring. Preliminary findings also suggest that CPX-351-treated patients with prior
stem cell transplant may be at risk for poorer outcomes and simultaneously raise the
possibility that CPX-351 patients with no prior history of transplant may have improvements
in response rate and 60-day mortality. All of these findings are preliminary but are consistent
with observations from a companion randomized Phase II study suggesting that AML
patients with poor risk characteristics may have improved outcomes in the newly diagnosed
AML setting (In press, Blood). Observations from this study extend and support the
rationale behind an ongoing randomized Phase III trial being conducted in patients with high
risk (secondary) AML.
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Figure 1.

CONSORT diagram.
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Figure 2.

EFS and OS Kaplan-Meier curves.
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Intensive Salvage Regimens in Control Arm
n
Mitoxantrone/Etoposide/Cytarabine

23

Idarubicin/Cytarabine

8

Other Cytarabine-based* induction:
+Fludarabine ± gemtuzumab ozogamicin

5

+Amsacrine

2

+Mitoxantrone ± gemtuzumab ozogamicin

2

+Gemtuzumab ozogamicin

1

+Cladribine

1

Author Manuscript

Cytarabine* alone

1

Mitoxantrone + Etoposide

1

*

Cytarabine was usually administered at doses >1gm/m2/dose.
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HSCT before Relapse

Age at First Relapse (years)

Cytogenetics at Diagnosis

Relapse-free Interval from CR1 (months)

Risk Group

European Prognostic Index Factors

2
0

> 45
No

0

≤ 35

1

5

36 – 45

3

Other

0

Inv(16) or t(16;16)
t(8;21)

5

≤6

0

> 18
3

8–14

Poor

6–18

7–9

1–6

59 (72.8)

57 (70.4)

14 (17.3)

10 (12.3)

72 (88.9)

2 (2.5)

7 (8.6)

27 (33.3)

43 (53.1)

11 (13.6)

56 (69.1)

16 (19.8)

9 (11.1)

0 (0.0)

> 100×109/L
Points

16 (19.8)

65 (80.2)

20 – 100×109/L

10 (12.3)

< 20 × 109/L

71 (87.7)

De novo AML
Secondary AML

70 (86.4)

52

Caucasian

13 (16.0)

61 – 65 yr

68 (84.0)

18 – 60 yr

Median (yr)

38 (46.9)

Intermediate

Favorable

WBC at Baseline

AML Type

Race

Age Group

Gender

37 (84.1)

33 (75.0)

7 (15.9)

4 (9.1)

39 (88.6)

1 (2.3)

4 (9.1)

16 (36.4)

20 (45.5)

8 (18.2)

29 (65.9)

9 (20.5)

6 (13.6)

1 (2.3)

5 (11.4)

38 (86.4)

3 (6.8)

41 (93.2)

36 (81.8)

56

9 (20.5)

35 (79.5)

19 (43.2)

n=44

n (%)

n=81

n (%)

Male

Author Manuscript

Demographics

Salvage

CPX-351

All Patients

39 (69.6)

47 (83.9)

5 (8.9)

4 (7.1)

56 (100)

0 (0.0)

0 (0.0)

26 (46.4)

30 (53.6)

0 (0.0)

56 (100)

--

--

0 (0.0)

11 (19.6)

45 (80.4)

9 (16.1)

47 (83.9)

50 (89.3)

56

12 (21.4)

44 (78.6)

25 (44.6)

n=56

n (%)

CPX-351

24 (82.8)

26 (89.7)

1 (3.4)

2 (6.9)

29 (100)

0 (0.0)

0 (0.0)

16 (55.2)

12 (41.4)

1 (3.4)

29 (100)

--

--

1 (3.4)

5 (17.2)

23 (11.5)

1(3.4)

28 (96.6)

26 (89.7)

58

8 (27.6)

21 (72.4)

11 (37.9)

n=29

n (%)

Salvage

Poor Risk Patients
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Post Induction HSCT
6 (7.4)
10 (12.3)

CRi
NR

22 (27.2)

CR

8.5

4.0

38 (46.9)

-ALL

--

OS (median, mos.)

15 (18.5)

90 days

6 (7.4)
12 (14.8)

8 (18.2)

22 (27.2)

Poor
30 days
60 days

5 (11.4)

11 (13.6)

Intermediate

5 (11.4)

4 (9.1)

12 (27.3)

21 (47.7)

6.3

1.5

13 (29.5)

7 (15.9)

2 (4.5)

5 (11.4)

7 (8.6)

Favorable

4 (9.1)

14 (31.8)

10 (12.3)

30 (37.0)

18 (40.9)

25/42* (59.5)

7 (15.9)

CRi

CR

40 (49.4)

CR+CRi

EFS (median, mos.)

Early Mortality

Response (CR+CRi)

58/75* (77.3)

22 (27.2)

MLFS*

2

n=44

n (%)

n (%)
n=81

Salvage

CPX-351

9 (16.1)

4 (7.1)

10 (17.6)

23 (41.1)

6.6

2.0

12 (21.4)

9 (16.1)

5 (8.9)

22 (39.3)

--

--

6 (10.7)

16 (28.6)

22 (39.3)

37/56 (66.1)

17 (30.6)

n=56

n (%)

CPX-351

4 (13.8)

2 (6.9)

5 (17.2)

11 (37.9)

4.2

1.2

11 (37.9)

7 (24.1)

2 (6.9)

8 (27.6)

--

--

2 (6.9)

6 (20.7)

8 (27.6)

13/29 (44.8)

5 (17.2)

n=29

n (%)

Salvage

SixCPX-351 patients and two Control patients did not have a Day 14-21 bone marrow. MLFS= morphologic leukemia-free state: bone marrow blasts <5% absence of Auer rods and extramedullary disease
on or after Day 14

*
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Poor Risk Patients
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All Patients
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7 (9)
9 (11)
7 (9)
4 (5)
4 (5)
2 (3)
4 (5)

Hypokalemia

Rash

Pyrexia

Acute Renal Failure3

Hypertension

Malignant Neoplasm Progressive4

Cellulitis

2 (5)

0 (0)

3 (7)

3 (7)

1 (2)

0 (0)

3 (7)

5 (11)

1 (2)

1 (2)

2 (5)

17 (39)

14 (32)

Salvage
n=44
n(%)

0 (0)

1 (1)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

1 (1)

5 (6)

3 (4)

3 (4)

1 (1)

includes AML and Leukemic Infiltration

includes Renal Failure and Renal Tubular Necrosis

4

3

includes UTI Enterococcal

2

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

2 (5)

0 (0)

1 (2)

1 (2)

Salvage
n=44
n(%)

Grade 4
CPX-351
n=81
n(%)

includes Pneumocystis, Bacterial Pneumonia and Fungal Pneumonia

1

5 (6)

11 (14)

Fatigue

Urinary Tract Infection2

2 (3)

Sepsis

11 (14)

21 (26)

Bacteremia

Pneumonia1

43 (53)

Febrile Neutropenia

CPX-351
n=81
n(%)

Grade 3

0 (0)

2 (3)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

4 (5)

4 (5)

0 (0)

0 (0)

CPX-351
n=81
n(%)

0 (0)

2 (5)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

2 (5)

1 (2)

0 (0)

Salvage
n=44
n(%)

Grade 5

4 (5)

5 (6)

4 (5)

4 (5)

7 (9)

9 (11)

7 (9)

5 (6)

12 (15)

11 (14)

18 (22)

24 (30)

44 (54)

CPX-351
n=81
n(%)

2 (5)

2 (5)

3 (7)

3 (7)

1 (2)

0 (0)

3 (7)

5 (11)

1 (2)

3 (7)

4 (9)

19 (43)

15 (34)

Salvage
n=44
n(%)

Grades 3–5

Author Manuscript

Non-Hematologic Treatment Emergent Adverse Events
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Outcome by Prior Exposure to HSCT
Prior HSCT

No Prior HSCT

n=29

(n=96)

CPX-351
n=22

Salvage
n=7

CPX-351
n=59

Salvage
n=37

n (%)

n (%)

n (%)

n (%)

8 (36.4)

4 (57.1)

32 (54.2)

14 (37.8)

0/0

0/0

7/9 (77.8)

5/6 (83.3)

EPI Intermediate Risk

3/5 (60.0)

1/2 (50.0)

8/11 (72.7)

4/7 (57.1)

EPI Poor Risk

5/17 (29.4)

3/5 (60.0)

17/39 (43.6)

5/24 (20.8)

30 Day Mortality

4 (18.2)

0

2 (3.4)

2 (5.4)

60 Day Mortality

6 (27.3)

1 (14.3)

6 (10.2)

6 (16.2)

CR+ CRi
EPI Favorable Risk
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